Resistance to doxorubicin correlated with dysregulation of microRNA-451 and P-glyoprotein, caspase 3, estrogen Receptor on Breast Cancer cell line

https://doi.org/10.19106/JMedSci005104201901

Indwiani Astuti(1*), Torizal GF(2), Sa’adah N(3), Oktriani R(4), Wardana T(5), Ysrafil .(6), Teguh Aryandono(7), Sofia Mubarika(8)

(1) Department of Pharmacology and Therapy, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta 55281, Indonesia
(2) Study Program of Biotechnology, Graduate School, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta,
(3) Master in Biomedical Sciences Program, Postgradeate Program, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta,
(4) Department of Biochemistry, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta,
(5) Faculty of Medicine, Jenderal Soedirman University, Banyumas, Central Java,
(6) Master in Biomedical Sciences Program, Postgradeate Program, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta,
(7) Department of Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
(8) Departement of Histology and Biology Cell, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
(*) Corresponding Author

Abstract


Doxorubicin (Dox)has beenused widely in breast cancer therapy. One of the problems in chemotherapy is the development of resistance to chemotherapy that lead to metastasis and relapse aggressiveness of cancer. MicroRNAs (miRNAs) are small non-coding RNA that regulate protein expression and play role in carcinogenesis, as well as cancer chemotherapy resistance. MiR-451 is classified as tumour suppressor miRNA, that binds to messenger RNA (mRNA) of MDR1, and leads disruption of  P-glycoprotein (Pgp) expression. Thestudy aimed to investigate the association between miR-451 and Pgp related with Dox resistance mechanism. In silico analysis was conducted to predict the binding affinity between miR-451 and mRNA of MDR1. The MCF-7 cell line was used as wild type model, while MCF-7/Dox was used as a model of resistance. qPCR was conducted to calculated miR-451 expression and immunocytochemistry was used to observe Pgp expression. miRNA was down-regulated in both on MCF-7 and MCF-7/Dox. On the other hand, Pgp expression was detectable in the cytoplasmic and cytoplasmic membrane in MCF-7/Dox. The Pgp expression was higher in the MCF-7/Dox compared to MCF-7. In conlusion, the over expression of Pgp is associated with the resistance to MCF-7/Dox.


Keywords


Doxorubicine; MicroRNA-145; Resistance; MCF-7 Cell Line

Full Text:

PDF


References

  1. Khan M, Pelengaris S. The molecular biology of cancer. Oxford (UK): Blackwell Publishing, 2006.
  2. Weber GF. Molecular mechanisms of cancer. London: Springer Science & Business Media; 2007.
  3. Nana-Sinkam SP, Croce CMJTR. Micrornas as therapeutic targets in cancer. Transl Res 2011;157(4):216-25. https://doi.org/10.1016/j.trsl.2011.01.013
  4. Brown KJ, Fenselau C. Investigation of doxorubicin resistance in MCF-7 breast cancer cells using shot-gun comparative proteomics with proteolytic 18O labeling. J Proteome Res 2004;3(3):455-62. https://doi.org/10.1021/pr0340835
  5. Katzung BG. Basic and clinical pharmacology. San Francisco: McGraw-Hill Education; 2017.
  6. Lukyanova NY, Rusetskya N, Tregubova N, Chekhun VJEo. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin. Exp Oncol 2009, 31(2) 87-91.
  7. Rusetskaya N, Lukyanova NY, Chekhun VJEo. Molecular profile and cell cycle in MCF-7 and MCF‑7/Dox cells exposed to conventional and liposomal forms of doxorubicin. Exp Oncol 2009, 31(3): 140-3.
  8. Gerlinger M, Rowan AJ, Horswell S, Larkin J, Endesfelder D, Gronroos E, et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. New Eng J Med 2012;366(10):883-92. https://doi.org/10.1056/NEJMoa1113205
  9. Choi C-HJCci. ABC transporters as multidrug resistance mechanisms and the development of chemosensitizers for their reversal. Cancer Cell Int 2005;5(1):30. https://doi.org/10.1186/1475-2867-5-30
  10. Krech T, Scheuerer E, Geffers R, Kreipe H, Lehmann U, Christgen MJCl. ABCB1/MDR1 contributes to the anticancer drug-resistant phenotype of iph-926 human lobular breast cancer cells. Cancer Lett 2012;315(2):153-60. https://doi.org/10.1016/j.canlet.2011.09.038
  11. Wind N & Holen I. Multidrug resistance in breast cancer: from in vitro models to clinical studies. Int J Breast Cancer 2011;2011.967419. https://doi.org/10.4061/2011/967419
  12. Kovalchuk O, Filkowski J, Meservy J, Ilnytskyy Y, Tryndyak VP, Chekun VF, et al. Involvement of microrna-451 in resistance of the MCF-7 breast cancer cells to chemotherapeutic drug doxorubicin. Mol Cancer Ther 2008;7(7):2152-9. https://doi.org/10.1158/1535-7163.MCT-08-0021
  13. Ajit SKJS. Circulating micrornas as biomarkers, therapeutic targets, and signaling molecules. Sensors 2012;12(3):3359-69. https://doi.org/10.3390/s120303359
  14. Brennecke J, Stark A, Russell RB, Cohen SMJPb. Principles of microrna-target recognition. PLoS Biol 2005;3(3):e85. https://doi.org/10.1371/journal.pbio.0030085
  15. Leitner AJT. MicroRNA target prediction. [Thesis]. Institute for Genomics and Bioinformatics Grz University of Technology Petersgsse, Austria.
  16. McCubrey JA, Steelman LS, Abrams SL, Lee JT, Chang F, Bertrand FE, et al. Roles of the RAF/MEK/ERK and PI3K/PTEN/AKT pathways in malignant transformation and drug resistance. Adv Enzyme Regul 2006;46(1):249-79. https://doi.org/10.1016/j.advenzreg.2006.01.004
  17. Davis JM, Navolanic PM, Weinstein-Oppenheimer CR, Steelman LS, Hu W, Konopleva M, et al. Raf-1 and Bcl-2 induce distinct and common pathways that contribute to breast cancer drug resistance. Clin Cancer Res 2003;9(3):1161-70.
  18. Benes V & Castoldi MJM. Expression profiling of microrna using Real-Time Quantitative PCR, how to use it and what is available. Methods 2010;50(4):244-9. https://doi.org/10.1016/j.ymeth.2010.01.026
  19. Gerbi SA, Lange TSJMbotc. All small nuclear RNAs (snRNAs) of the [U4/U6. U5] tri-snRPN localize to nucleoli; identification of the nucleolar localization element of U6 snRNA. Mol Biol Cell 2002;13(9):3123-37. https://doi.org/10.1091/mbc.01-12-0596
  20. Lee C, Jaladat Y, Mohammadi A, Sharifi A, Geisler S, Valadkhan SJR. Metal binding and substrate positioning by evolutionarily invariant U6 sequences in catalytically active protein-free snRNAs. RNA 2010;16(11):2226-38. https://doi.org/10.1261/rna.2170910
  21. Osborne CK, Hobbs K, Trent JM. Biological differences among MCF-7 human breast cancer cell lines from different laboratories. Breast Cancer ResTreat 1987;9(2):111-21. https://doi.org/10.1007/BF01807363
  22. Huang HL, Hsing HW, Lai TC, Chen YW, Lee TR, Chan HT, et al. Trypsin-induced proteome alteration during cell subculture in mammalian cells. J Biomed Sci 2010;17(1):36. https://doi.org/10.1186/1423-0127-17-36
  23. Ryland GL, Bearfoot JL, Doyle MA, Boyle SE, Choong DY, Rowley SM, et al. Microrna genes and their target 3′-untranslated regions are infrequently somatically mutated in ovarian cancers. PLoS One 2012;7(4):e35805. https://doi.org/10.1371/journal.pone.0035805
  24. Jansson MD & Lund AH. MicroRNA and cancer. Mol Oncol 2012;6(6):590-610. https://doi.org/10.1016/j.molonc.2012.09.006



DOI: https://doi.org/10.19106/JMedSci005104201901

Article Metrics

Abstract views : 1800 | views : 2583


Bookmark and Share


Copyright (c) 2019 Indwiani Astuti, Torizal GF, Sa’adah N, Oktriani R, Wardana T, Ysrafil ., Teguh Aryandono, Sofia Mubarika

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.